Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase III for Solid Tumor. According to GlobalData, Phase III drugs for Solid Tumor have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Adagrasib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Adagrasib overview

Adagrasib (Krazati) belongs to the RAS GTPase family, an antineoplastic agent. It is formulated as film coated tablets for oral route of administration. Krazati is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

Adagrasib is under development for the treatment of solid tumors including advanced colorectal cancer, advanced breast cancer, advanced pancreatic cancer, advanced uterine cancer, gynecological cancer, epithelial ovarian cancer, squamous or non-squamous non-small cell lung cancer, colorectal cancer, breast cancer, glioblastoma multiforme, gastroesophageal (GE) junction carcinomas, ovarian cancer, endometrial cancer, bile duct cancer, metastatic pancreatic cancer and pancreatic ductal adenocarcinoma. It is administered by the oral route as a tablet. The drug candidate acts by targeting KRAS G12C mutations.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.

For a complete picture of Adagrasib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.